Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Drug PIC

NMPA Approves Novartis’ Pluvicto Plus ARPI for PSMA‑Positive mHSPC in China, Advancing Radioligand Therapy to Earlier Prostate Cancer

Fineline Cube Aug 26, 2026
Company Drug PIC

FDA Approves J&J’s IMAAVY for Warm Autoimmune Hemolytic Anemia, Marking Second Indication for Nipocalimab

Fineline Cube Aug 26, 2026
Company Drug PIC

FDA Approves BeOne’s Tevimbra Plus Zanidatamab and Chemotherapy for First‑Line HER2‑Positive Gastroesophageal Adenocarcinoma

Fineline Cube Aug 26, 2026
Company Drug PIC

MHLW Approves Takeda’s First‑in‑Class ORZEYFUL (Oveporexton) for Narcolepsy Type 1 in Japan

Fineline Cube Aug 26, 2026
Company PIC

WuXi Biologics 2026H1 Revenue Climbs 18.4% to RMB 11.8 Billion as Project Pipeline Hits 1,064 Integrated Programs

Fineline Cube Aug 26, 2026
Company Drug PIC

NMPA Approves Novartis’ Pluvicto Plus ARPI for PSMA‑Positive mHSPC in China, Advancing Radioligand Therapy to Earlier Prostate Cancer

Fineline Cube Aug 26, 2026
Company Drug PIC

NMPA Approves Novartis’ Pluvicto Plus ARPI for PSMA‑Positive mHSPC in China, Advancing Radioligand Therapy to Earlier Prostate Cancer

Fineline Cube Aug 26, 2026
Company Drug PIC

FDA Approves J&J’s IMAAVY for Warm Autoimmune Hemolytic Anemia, Marking Second Indication for Nipocalimab

Fineline Cube Aug 26, 2026
Company Deals

Organon In-Licenses Eli Lilly’s Emgality and Rayvow for European Migraine Market

Fineline Cube Dec 19, 2023

Organon (NYSE: OGN), a specialist in women’s health, has in-licensed migraine treatments Emgality (galcanezumab) and...

Company Drug

European Commission Expands Keytruda Indications for Advanced Cancer Treatments

Fineline Cube Dec 19, 2023

The European Commission (EC) has granted Merck, Sharp & Dohme (MSD; NYSE: MRK) additional indications...

Company Drug

HuidaGene Secures Rare Pediatric Disease Designation for CRISPR Therapy HG302 Targeting DMD

Fineline Cube Dec 19, 2023

HuidaGene Therapeutics, based in China, has announced that it has received Rare Pediatric Disease Designation...

Company Deals

Blue Sail Medical Partners with Weifang Government on Healthcare Initiative

Fineline Cube Dec 19, 2023

China’s Blue Sail Medical Co., Ltd. (SHE: 002382) has announced strategic cooperation agreements with the...

Company Drug

HighField Biopharmaceutical Doses First Patient in HFK1 Clinical Trial Targeting Solid Tumors

Fineline Cube Dec 19, 2023

Hangzhou-based HighField Biopharmaceutical, a leader in immuno-oncology focused on innovative lipid-based therapies, has announced the...

Company Deals

Kangtai Biological Partners with Bahrain Pharma Firm on Strategic Vaccine Production Agreement

Fineline Cube Dec 19, 2023

Shenzhen Kangtai Biological Products Co., Ltd. (SHE: 300601), a prominent player in China’s biotechnology sector,...

Company Drug

EMA’s CHMP Gives Green Light to Sanofi’s Fexinidazole for Acute Sleeping Sickness Treatment

Fineline Cube Dec 19, 2023

Last week, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines...

Company Medical Device

BGI Genomics Receives NMPA Approval for Innovative Colorectal Cancer Detection Kit

Fineline Cube Dec 19, 2023

BGI Genomics Co., Ltd. (SHE: 300676), a leading genomics firm based in China, has announced...

Company Drug

InventisBio’s KRAS G12C Inhibitor D-1553 Advances Toward Priority Review in China

Fineline Cube Dec 19, 2023

According to the China Center for Drug Evaluation (CDE), Shanghai-based InventisBio Co., Ltd. (SHA: 688382)...

Company

GSK’s CCO Calls China a Hotbed for Innovative Molecules and Licensing Deals

Fineline Cube Dec 19, 2023

In an interview with the Financial Times, Luke Miels, Chief Commercial Officer of UK-based GlaxoSmithKline...

Company Deals

Biocytogen and Ona Therapeutics Forge Antibody Evaluation and Licensing Agreement

Fineline Cube Dec 19, 2023

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315), based in China, has entered into an antibody...

Company Deals

WuXi Biologics Partners with Visen Pharmaceuticals for Lonapegsomatropin Manufacturing

Fineline Cube Dec 19, 2023

China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has entered into...

Company Drug

Keytruda Gains 12th Indication Approval in China for HER2-Negative Gastric Cancer

Fineline Cube Dec 19, 2023

US pharmaceutical giant Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that its immunotherapy...

Company Drug

Sirnaomics Ltd Granted FDA Approval for Phase I RSV mRNA Vaccine Study

Fineline Cube Dec 19, 2023

Sirnaomics Ltd (HKG: 2257) has received approval from the US Food and Drug Administration (FDA)...

Company Drug

Roche Receives NMPA Approval for Ophthalmology BsAb Vabysmo (Farcimab) for Diabetic Macular Edema

Fineline Cube Dec 19, 2023

Swiss pharmaceutical giant Roche (SWX: ROG) has announced that it has obtained marketing approval from...

Company Drug

Huadong Medicine Gets NMPA Green Light for Clinical Study of Ryzodeg Biosimilar

Fineline Cube Dec 19, 2023

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received approval from...

Company Deals

Fosun Pharmaceutical Secures GHIT Fund Investment for Malaria Drug Trial

Fineline Cube Dec 18, 2023

Shanghai Fosun Pharmaceutical Co., Ltd (SHA: 600196, HKG: 2196) has received financial backing of JPY...

Company Drug

FDA Approves Pfizer-Astellas-MSD Combo Therapy for Advanced Urothelial Cancer

Fineline Cube Dec 18, 2023

Pfizer (NYSE: PFE), Astellas (TYO: 4503), and Merck, Sharp & Dohme (MSD; NYSE: MRK) have...

Medical Device Policy / Regulatory

China Releases Emergency Use Rules for Medical Devices Amid Public Health Emergencies

Fineline Cube Dec 18, 2023

The National Medical Products Administration (NMPA), National Health Commission (NHC), and Chinese Center for Disease...

Company Deals

Novo Nordisk Acquires Alkermes’ Irish Production Site for $92.5 Million to Boost GLP-1 Output

Fineline Cube Dec 18, 2023

Novo Nordisk (CPH: NOVO-B), a Danish pharmaceutical giant, has reached an agreement to acquire a...

Posts pagination

1 … 474 475 476 … 712

Recent updates

  • NMPA Approves Novartis’ Pluvicto Plus ARPI for PSMA‑Positive mHSPC in China, Advancing Radioligand Therapy to Earlier Prostate Cancer
  • FDA Approves J&J’s IMAAVY for Warm Autoimmune Hemolytic Anemia, Marking Second Indication for Nipocalimab
  • FDA Approves BeOne’s Tevimbra Plus Zanidatamab and Chemotherapy for First‑Line HER2‑Positive Gastroesophageal Adenocarcinoma
  • MHLW Approves Takeda’s First‑in‑Class ORZEYFUL (Oveporexton) for Narcolepsy Type 1 in Japan
  • WuXi Biologics 2026H1 Revenue Climbs 18.4% to RMB 11.8 Billion as Project Pipeline Hits 1,064 Integrated Programs
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug PIC

NMPA Approves Novartis’ Pluvicto Plus ARPI for PSMA‑Positive mHSPC in China, Advancing Radioligand Therapy to Earlier Prostate Cancer

Company Drug PIC

FDA Approves J&J’s IMAAVY for Warm Autoimmune Hemolytic Anemia, Marking Second Indication for Nipocalimab

Company Drug PIC

FDA Approves BeOne’s Tevimbra Plus Zanidatamab and Chemotherapy for First‑Line HER2‑Positive Gastroesophageal Adenocarcinoma

Company Drug PIC

MHLW Approves Takeda’s First‑in‑Class ORZEYFUL (Oveporexton) for Narcolepsy Type 1 in Japan

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2026 | Fineline Information & Technology | BlogData by Themeansar.